Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T-cells for AML Expressing CLL-1 Antigen
NCT04219163Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2020
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CLL-1 CAR-T in acute myeloid leukemia (AML), sponsored by Baylor College of Medicine. Primary endpoint: Dose limiting toxicity rate at 4 weeks. Started Jul 2020; status: active, not recruiting.
02
Drugs
anti-CLL-1 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04219163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219163.